Pub Date : 2026-03-18eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S576249
Nur Aisyah, Jihan Sadira Aurellia, Widya Norma Insani
Purpose: Calcium channel blockers (CCBs) are widely used as first-line therapy for hypertension, but concerns remain regarding their long-term safety and effectiveness. This review aims to systematically summarize the existing evidence on the long-term safety and effectiveness of CCBs in patients with hypertension.
Methods: A systematic review was conducted using the PubMed database to identify randomized controlled trials (RCTs), cohort studies, and case-control studies assessing the long-term use (≥1 year) of CCBs in adult hypertensive populations. Eligible studies compared CCBs with other antihypertensive agents or placebo and reported outcomes related to systemic safety and effectiveness. The quality of each study was assessed using the Jadad and Newcastle-Ottawa Scales. Evidence was synthesized descriptively and stratified by organ system and clinical outcome.
Results: In total, 29 studies met the inclusion criteria, encompassing both RCTs and observational studies. Long-term CCB use was generally safe, with manageable risks. Renal protective effects were less consistent, while several studies reported a marginal increase in the incidence of new-onset diabetes. Associations with breast cancer remained inconclusive, and the risk of bone fractures appeared modestly reduced. Other systemic effects, including metabolic and reproductive changes, were generally mild. In terms of effectiveness, CCBs consistently reduced stroke incidence, although evidence regarding other cardiovascular outcomes, such as infarction, heart failure, and transient ischemic events, was inconsistent across studies.
Conclusion: Overall, CCBs are safe for long-term use and show sustained effectiveness in stroke and angina, although evidence for heart failure, myocardial infarction, and transient ischemic attack remains inconsistent.
{"title":"Long-Term Safety and Effectiveness of Calcium Channel Blockers in Hypertension: A Systematic Review.","authors":"Nur Aisyah, Jihan Sadira Aurellia, Widya Norma Insani","doi":"10.2147/DHPS.S576249","DOIUrl":"https://doi.org/10.2147/DHPS.S576249","url":null,"abstract":"<p><strong>Purpose: </strong>Calcium channel blockers (CCBs) are widely used as first-line therapy for hypertension, but concerns remain regarding their long-term safety and effectiveness. This review aims to systematically summarize the existing evidence on the long-term safety and effectiveness of CCBs in patients with hypertension.</p><p><strong>Methods: </strong>A systematic review was conducted using the PubMed database to identify randomized controlled trials (RCTs), cohort studies, and case-control studies assessing the long-term use (≥1 year) of CCBs in adult hypertensive populations. Eligible studies compared CCBs with other antihypertensive agents or placebo and reported outcomes related to systemic safety and effectiveness. The quality of each study was assessed using the Jadad and Newcastle-Ottawa Scales. Evidence was synthesized descriptively and stratified by organ system and clinical outcome.</p><p><strong>Results: </strong>In total, 29 studies met the inclusion criteria, encompassing both RCTs and observational studies. Long-term CCB use was generally safe, with manageable risks. Renal protective effects were less consistent, while several studies reported a marginal increase in the incidence of new-onset diabetes. Associations with breast cancer remained inconclusive, and the risk of bone fractures appeared modestly reduced. Other systemic effects, including metabolic and reproductive changes, were generally mild. In terms of effectiveness, CCBs consistently reduced stroke incidence, although evidence regarding other cardiovascular outcomes, such as infarction, heart failure, and transient ischemic events, was inconsistent across studies.</p><p><strong>Conclusion: </strong>Overall, CCBs are safe for long-term use and show sustained effectiveness in stroke and angina, although evidence for heart failure, myocardial infarction, and transient ischemic attack remains inconsistent.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"576249"},"PeriodicalIF":3.4,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-11eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S558001
Sandra Marquis, Renée O'Leary, N Esmé Marquis, Jennifer Baumbusch
This study asked the questions: what is known and what is not known about medication burden in adults with an intellectual disability. We used a rapid mapping review methodology to collate, describe and catalog the wide variety of evidence in this area. Ninety-one studies were included. Study characteristics, indicators of medication burden and sub-populations at increased risk were catalogued in a table and tabulated as tree maps. The authors concluded that there is evidence of a high medication burden in this population, and that the burden is highest in older adults with an ID, those living in supervised housing and those with diagnosed comorbidities and multi-morbidities. Areas that need further exploration are the total burden of medications used, including the age at which medications are first prescribed and the duration of medication use; the long-term effects of a high medication burden; and the long-term effects of anticholinergic burden. In addition, there is little information on the effects of demographic factors such as race and income.
{"title":"A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.","authors":"Sandra Marquis, Renée O'Leary, N Esmé Marquis, Jennifer Baumbusch","doi":"10.2147/DHPS.S558001","DOIUrl":"10.2147/DHPS.S558001","url":null,"abstract":"<p><p>This study asked the questions: what is known and what is not known about medication burden in adults with an intellectual disability. We used a rapid mapping review methodology to collate, describe and catalog the wide variety of evidence in this area. Ninety-one studies were included. Study characteristics, indicators of medication burden and sub-populations at increased risk were catalogued in a table and tabulated as tree maps. The authors concluded that there is evidence of a high medication burden in this population, and that the burden is highest in older adults with an ID, those living in supervised housing and those with diagnosed comorbidities and multi-morbidities. Areas that need further exploration are the total burden of medications used, including the age at which medications are first prescribed and the duration of medication use; the long-term effects of a high medication burden; and the long-term effects of anticholinergic burden. In addition, there is little information on the effects of demographic factors such as race and income.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"558001"},"PeriodicalIF":3.4,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12992441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147480118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-10eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S543301
Cheng Cheng, Yanfeng Han, Xiaoxi Liu, Weiwei Yu, Nannan Yang
Background: Hypersensitivity reaction to hyaluronidase, though rare, can occur following regional anesthesia in ophthalmic surgery and may mimic serious conditions such as orbital cellulitis. Prompt recognition is critical to avoid misdiagnosis and unnecessary interventions.
Case presentation: We report two cases of hypersensitivity reaction following hyaluronidase-augmented peribulbar anesthesia for cataract surgery. Case 1: A 90-year-old female with no prior allergy history developed progressive periorbital edema extending to the ipsilateral face and neck within 7 hours after surgery. Infection and hemorrhage were excluded via ultrasound. The reaction resolved promptly with antihistamines and systemic corticosteroids. Case 2: A 69-year-old female developed progressive bilateral periorbital edema extending to the forehead, accompanied by moderate pain within 7 hours postoperatively. While her C-reactive protein (CRP) level was within normal limits on the day of surgery, it rose significantly to 33.92 mg/L on postoperative day 1. Given this clinical and laboratory progression, an empirical and prophylactic therapeutic protocol was initiated, including a short course of systemic antibiotics alongside intensified anti-inflammatory treatment. All bacterial and fungal cultures returned negative, confirming a non-infectious etiology. Both patients achieved complete resolution of symptoms with uneventful recoveries maintained at both the one-week and one-month postoperative follow-up visits.
Conclusion: These cases illustrate that hyaluronidase hypersensitivity, though uncommon, should be considered in the differential diagnosis of acute postoperative periorbital inflammation. A combination of clinical vigilance, targeted imaging, and judicious use of laboratory tests is key to distinguishing this condition from infectious complications. Early diagnosis and a structured management approach are crucial to ensure patient safety and optimal outcomes.
{"title":"Hypersensitivity Reaction to Hyaluronidase After Peribulbar Anesthesia for Cataract Surgery: Two Case Reports.","authors":"Cheng Cheng, Yanfeng Han, Xiaoxi Liu, Weiwei Yu, Nannan Yang","doi":"10.2147/DHPS.S543301","DOIUrl":"https://doi.org/10.2147/DHPS.S543301","url":null,"abstract":"<p><strong>Background: </strong>Hypersensitivity reaction to hyaluronidase, though rare, can occur following regional anesthesia in ophthalmic surgery and may mimic serious conditions such as orbital cellulitis. Prompt recognition is critical to avoid misdiagnosis and unnecessary interventions.</p><p><strong>Case presentation: </strong>We report two cases of hypersensitivity reaction following hyaluronidase-augmented peribulbar anesthesia for cataract surgery. Case 1: A 90-year-old female with no prior allergy history developed progressive periorbital edema extending to the ipsilateral face and neck within 7 hours after surgery. Infection and hemorrhage were excluded via ultrasound. The reaction resolved promptly with antihistamines and systemic corticosteroids. Case 2: A 69-year-old female developed progressive bilateral periorbital edema extending to the forehead, accompanied by moderate pain within 7 hours postoperatively. While her C-reactive protein (CRP) level was within normal limits on the day of surgery, it rose significantly to 33.92 mg/L on postoperative day 1. Given this clinical and laboratory progression, an empirical and prophylactic therapeutic protocol was initiated, including a short course of systemic antibiotics alongside intensified anti-inflammatory treatment. All bacterial and fungal cultures returned negative, confirming a non-infectious etiology. Both patients achieved complete resolution of symptoms with uneventful recoveries maintained at both the one-week and one-month postoperative follow-up visits.</p><p><strong>Conclusion: </strong>These cases illustrate that hyaluronidase hypersensitivity, though uncommon, should be considered in the differential diagnosis of acute postoperative periorbital inflammation. A combination of clinical vigilance, targeted imaging, and judicious use of laboratory tests is key to distinguishing this condition from infectious complications. Early diagnosis and a structured management approach are crucial to ensure patient safety and optimal outcomes.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"543301"},"PeriodicalIF":3.4,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12912024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146219032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-24eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S583501
Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi
Introduction: Long-term use of proton pump inhibitors (PPIs) requires careful observation with endoscopy in Japan. However, there are no studies examining whether monitoring is being properly carried out in clinical practice. Thus, we investigate the usage of PPIs by the presence or absence of endoscopic monitoring using a claims database.
Methods: This study was a retrospective observational cohort study using the nationwide claims database. We obtained data of patients diagnosed with GERD (excluding suspected cases) between April 2014 and March 2024. Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. To assess the duration of prescriptions over a one-year period, the medication possession ratio (MPR) showing the prescription days per year ratio was examined. MPR was compared between patients who underwent endoscopy [endoscopy(+) group] and those who did not [endoscopy(-) group] during the follow-up period of 12 months.
Results: A total of 398,253 patients [endoscopy(+) group: 142,653; endoscopy(-) group: 255,600] were included in the analysis. The median MPR was 0.534 in the endoscopy(+) group and 0.805 in the endoscopy(-) group; MPR was significantly higher in the endoscopy(-) group (p < 0.0001).
Conclusion: These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety.
{"title":"Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan.","authors":"Akina Takami, Gen Terashima, Yuichi Shiotsuki, Koki Yamashita, Ataru Igarashi","doi":"10.2147/DHPS.S583501","DOIUrl":"https://doi.org/10.2147/DHPS.S583501","url":null,"abstract":"<p><strong>Introduction: </strong>Long-term use of proton pump inhibitors (PPIs) requires careful observation with endoscopy in Japan. However, there are no studies examining whether monitoring is being properly carried out in clinical practice. Thus, we investigate the usage of PPIs by the presence or absence of endoscopic monitoring using a claims database.</p><p><strong>Methods: </strong>This study was a retrospective observational cohort study using the nationwide claims database. We obtained data of patients diagnosed with GERD (excluding suspected cases) between April 2014 and March 2024. Inclusion criteria were patients aged 18 years or older, continuously prescribed drugs of interest (omeprazole, lansoprazole, rabeprazole, esomeprazole, and vonoprazan) for 8 weeks or more. To assess the duration of prescriptions over a one-year period, the medication possession ratio (MPR) showing the prescription days per year ratio was examined. MPR was compared between patients who underwent endoscopy [endoscopy(+) group] and those who did not [endoscopy(-) group] during the follow-up period of 12 months.</p><p><strong>Results: </strong>A total of 398,253 patients [endoscopy(+) group: 142,653; endoscopy(-) group: 255,600] were included in the analysis. The median MPR was 0.534 in the endoscopy(+) group and 0.805 in the endoscopy(-) group; MPR was significantly higher in the endoscopy(-) group (p < 0.0001).</p><p><strong>Conclusion: </strong>These findings revealed that the long-term administration of PPIs without monitoring esophageal mucosa by endoscopy in patients with GERD is a common practice in Japan. However, compliance with the package inserts suggesting adequate observation, including periodic endoscopic examinations, should be highlighted to ensure safety.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"583501"},"PeriodicalIF":3.4,"publicationDate":"2026-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13012140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147510767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-22eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S548441
Deogratias M Katabalo, Esther Njile, Benson R Kidenya, Anthony Cuthbert Liwa, Kristin Schroeder
Background: Chemotherapy remains the cornerstone of pediatric cancer treatment, yet its cytotoxic nature often results in chemotherapy-induced toxicities, adverse effects arising from damage to healthy, rapidly dividing cells. Data describing these toxicities from the patient and caregiver perspective are scarce in sub-Saharan Africa. This study assessed the types, severity, and determinants of Chemotherapy-Induced Toxicities among pediatric cancer patients in Tanzania.
Methodology: A descriptive cross-sectional study was conducted over six months at Bugando Medical Center. Pediatric patients aged birth to 18 years receiving chemotherapy were enrolled. Toxicities were assessed using a locally validated, Swahili-translated version of the Pediatric Patient-Reported Outcomes Common Terminology Criteria for Adverse Events tool. Children aged ≥ 7 years self-reported their symptoms, while caregivers provided proxy reports for younger children and those who can not express themselves. Associations between chemotherapy-induced toxicities and demographic or treatment variables were analysed using multivariate logistic regression to adjust for potential confounding factors or variables (p < 0.05).
Results: Of 120 participants (55.8% male), all experienced at least one Chemotherapy-Induced Toxicity, with a mean of five per participant. The most common toxicities were alopecia (82.5%), taste changes (74.2%), vomiting (44.2%), and nausea (35%). Most events were mild (grade 1). In multivariable analysis, cancer classification was the only significant predictor of toxicity, with solid tumors showing higher odds of ≥ Grade 2 Chemotherapy-induced toxicities compared with hematologic cancers (AOR = 7.42, p = 0.047). Other factors showed no statistically significant associations.
Conclusion: Chemotherapy-induced toxicities were frequent, with most children experiencing multiple symptoms across organ systems. Cancer classification was the only factor significantly associated with higher-grade toxicities. Integrating child- and caregiver-reported outcome measures into pediatric oncology practice could enhance early identification of toxicities, support timely management, and inform national strategies to improve treatment safety and quality of life for children with cancer in Tanzania.
背景:化疗仍然是儿童癌症治疗的基石,但其细胞毒性往往导致化疗引起的毒性,以及对健康、快速分裂的细胞的损害所产生的不良反应。在撒哈拉以南非洲,从患者和护理人员的角度描述这些毒性的数据很少。本研究评估了坦桑尼亚儿童癌症患者化疗引起的毒性的类型、严重程度和决定因素。方法:在布干多医疗中心进行了为期六个月的描述性横断面研究。出生至18岁接受化疗的儿科患者被纳入研究。使用当地验证的斯瓦希里语翻译版本的儿科患者报告结果不良事件通用术语标准工具评估毒性。≥7岁的儿童自行报告症状,而照顾者为年龄较小的儿童和不能表达自己的儿童提供代理报告。使用多变量逻辑回归分析化疗引起的毒性与人口统计学或治疗变量之间的关系,以校正潜在的混杂因素或变量(p < 0.05)。结果:在120名参与者中(55.8%为男性),所有参与者都经历了至少一次化疗引起的毒性,平均每个参与者5次。最常见的毒性是脱发(82.5%)、味觉改变(74.2%)、呕吐(44.2%)和恶心(35%)。大多数事件为轻度(1级)。在多变量分析中,癌症分类是毒性的唯一显著预测因子,与血液学癌症相比,实体肿瘤显示≥2级化疗诱导毒性的几率更高(AOR = 7.42, p = 0.047)。其他因素无统计学意义。结论:化疗引起的毒性是常见的,大多数儿童出现跨器官系统的多重症状。癌症分类是唯一与高级别毒性显著相关的因素。将儿童和护理人员报告的结果措施纳入儿科肿瘤学实践,可以加强毒性的早期识别,支持及时管理,并为坦桑尼亚提高癌症儿童治疗安全性和生活质量的国家战略提供信息。
{"title":"Chemotherapy-Induced Toxicities in Pediatric Cancer Patients: A Cross-Sectional Survey Using a Child- and Caregiver-Reported Outcome Tool in Tanzania.","authors":"Deogratias M Katabalo, Esther Njile, Benson R Kidenya, Anthony Cuthbert Liwa, Kristin Schroeder","doi":"10.2147/DHPS.S548441","DOIUrl":"https://doi.org/10.2147/DHPS.S548441","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy remains the cornerstone of pediatric cancer treatment, yet its cytotoxic nature often results in chemotherapy-induced toxicities, adverse effects arising from damage to healthy, rapidly dividing cells. Data describing these toxicities from the patient and caregiver perspective are scarce in sub-Saharan Africa. This study assessed the types, severity, and determinants of Chemotherapy-Induced Toxicities among pediatric cancer patients in Tanzania.</p><p><strong>Methodology: </strong>A descriptive cross-sectional study was conducted over six months at Bugando Medical Center. Pediatric patients aged birth to 18 years receiving chemotherapy were enrolled. Toxicities were assessed using a locally validated, Swahili-translated version of the Pediatric Patient-Reported Outcomes Common Terminology Criteria for Adverse Events tool. Children aged ≥ 7 years self-reported their symptoms, while caregivers provided proxy reports for younger children and those who can not express themselves. Associations between chemotherapy-induced toxicities and demographic or treatment variables were analysed using multivariate logistic regression to adjust for potential confounding factors or variables (p < 0.05).</p><p><strong>Results: </strong>Of 120 participants (55.8% male), all experienced at least one Chemotherapy-Induced Toxicity, with a mean of five per participant. The most common toxicities were alopecia (82.5%), taste changes (74.2%), vomiting (44.2%), and nausea (35%). Most events were mild (grade 1). In multivariable analysis, cancer classification was the only significant predictor of toxicity, with solid tumors showing higher odds of ≥ Grade 2 Chemotherapy-induced toxicities compared with hematologic cancers (AOR = 7.42, p = 0.047). Other factors showed no statistically significant associations.</p><p><strong>Conclusion: </strong>Chemotherapy-induced toxicities were frequent, with most children experiencing multiple symptoms across organ systems. Cancer classification was the only factor significantly associated with higher-grade toxicities. Integrating child- and caregiver-reported outcome measures into pediatric oncology practice could enhance early identification of toxicities, support timely management, and inform national strategies to improve treatment safety and quality of life for children with cancer in Tanzania.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"548441"},"PeriodicalIF":3.4,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-21eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S572681
Mary Madalen Angut, Humphrey Atwijukiire, Brian Mushabe, Katusabe Shamim, Brenda Namanda, Charles Mondo, Emmanuel Seremba, Charles Kabugo, Joseph Baruch Baluku
Background: Missed Medication Doses (MMD) are a common but preventable form of medication error that compromise treatment outcomes. Evidence on the burden and consequences of MMD among hospitalized people living with HIV (PLHIV) in Uganda remains limited.
Methods: We conducted a cross-sectional study at KNRH, Kampala, Uganda, reviewing medical records of PLHIV admitted to the infectious diseases unit between January 2022 and December 2023. Eligible files included treatment charts documenting prescribed and administered parenteral medications. Descriptive statistics summarized patient characteristics and prevalence of MMD. Associations between patient factors and MMD were assessed using chi-square tests and multivariable logistic regression. Outcomes examined included length of hospital stay, in-hospital mortality, and readmission.
Results: Of 814 records screened, 462 met the inclusion criteria. Patients were predominantly female (61.0%), with a mean age of 25.8 years (SD 14.4). Overall, 403 patients (87.2%; 95% CI: 84.1-90.0) experienced at least one MMD. Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Lower odds of MMD were independently associated with Luo ethnicity (aOR = 0.15, 95% CI: 0.03-0.59), separated marital status (aOR = 0.16, 95% CI: 0.03-0.73), and Muslim faith (aOR = 0.21, 95% CI: 0.07-0.61). Older age was associated with a modest increase in risk (aOR = 1.02 per year, p = 0.032). Length of hospital stay did not differ significantly between patients with and without MMD. Overall in-hospital mortality was high (69.0%) and was lower among patients with documented MMD compared to those without (p < 0.001).
Conclusion: Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes.
{"title":"Prevalence of Missed Medication Doses and Outcomes of Hospitalized Patients Living with HIV in Uganda.","authors":"Mary Madalen Angut, Humphrey Atwijukiire, Brian Mushabe, Katusabe Shamim, Brenda Namanda, Charles Mondo, Emmanuel Seremba, Charles Kabugo, Joseph Baruch Baluku","doi":"10.2147/DHPS.S572681","DOIUrl":"https://doi.org/10.2147/DHPS.S572681","url":null,"abstract":"<p><strong>Background: </strong>Missed Medication Doses (MMD) are a common but preventable form of medication error that compromise treatment outcomes. Evidence on the burden and consequences of MMD among hospitalized people living with HIV (PLHIV) in Uganda remains limited.</p><p><strong>Methods: </strong>We conducted a cross-sectional study at KNRH, Kampala, Uganda, reviewing medical records of PLHIV admitted to the infectious diseases unit between January 2022 and December 2023. Eligible files included treatment charts documenting prescribed and administered parenteral medications. Descriptive statistics summarized patient characteristics and prevalence of MMD. Associations between patient factors and MMD were assessed using chi-square tests and multivariable logistic regression. Outcomes examined included length of hospital stay, in-hospital mortality, and readmission.</p><p><strong>Results: </strong>Of 814 records screened, 462 met the inclusion criteria. Patients were predominantly female (61.0%), with a mean age of 25.8 years (SD 14.4). Overall, 403 patients (87.2%; 95% CI: 84.1-90.0) experienced at least one MMD. Missed doses were common across nearly all medications, with omission rates exceeding 80% for ceftriaxone, paracetamol, metronidazole, omeprazole, metoclopramide, and levofloxacin, and approaching 100% for furosemide, co-amoxiclav, ondansetron, enoxaparin, albumin, and artesunate. Lower odds of MMD were independently associated with Luo ethnicity (aOR = 0.15, 95% CI: 0.03-0.59), separated marital status (aOR = 0.16, 95% CI: 0.03-0.73), and Muslim faith (aOR = 0.21, 95% CI: 0.07-0.61). Older age was associated with a modest increase in risk (aOR = 1.02 per year, p = 0.032). Length of hospital stay did not differ significantly between patients with and without MMD. Overall in-hospital mortality was high (69.0%) and was lower among patients with documented MMD compared to those without (p < 0.001).</p><p><strong>Conclusion: </strong>Missed parenteral medication doses are highly prevalent among hospitalized PLHIV in Uganda. Strengthening medication administration and documentation systems is urgently needed to improve patient safety and outcomes.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"572681"},"PeriodicalIF":3.4,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-08eCollection Date: 2026-01-01DOI: 10.2147/DHPS.S556918
Saisai Gu
Purpose: Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals. This study aims to identify and characterize specific adverse events (AEs) associated with tirzepatide utilizing FDA Adverse Event Reporting System (FAERS).
Patients and methods: The datasets were cleaned and standardized using Python, a programming language for data processing, and MySQL, a database management system, to ensure accuracy and consistency before analysis. Subsequently, AE signals were detected via four quantitative disproportionality algorithms, sorted and categorized by demographics, gender, and clinical prioritization, with a modified Weibull model developed to analyze AE onset timing.
Results: A total of 67,305 cases (75.83% female) and 137,583 adverse events were identified related to tirzepatide. One hundred and forty-four AE signals showed statistically significant signals suggesting a potential association with tirzepatide, with several new including postmenopausal haemorrhage and menstrual disorder (implying regulatory interference on sex hormones), Wernicke's encephalopathy and sleep disorder (malnutrition caused by low intake). Pancreatitis, impaired gastric emptying, dehydration and cholelithiasis carried higher risks with serious clinical outcomes. Sleep disorder, delayed gastric emptying, and medullary thyroid cancer are more common in males; starvation ketoacidosis and incorrect injection site, in females. The median time-to-onset (TTO) was 6.36 days (Interquartile Range (IQR) 0.85-31.2) with the Weibull shape parameter (β) of 0.44, indicating an early failure profile.
Conclusion: This study uncovered new risks of tirzepatide, including AEs associated with skin, menstruation, psychiatric and nervous system. Median TTO was corrected to within a week, highlighting the need for early monitoring before clinicians prescribe tirzepatide, and special attention should be given to patients who have pre-existing digestive dysfunction, malnutrition, or a family history of thyroid disease.
{"title":"Adverse Events Associated with Tirzepatide: Updated Pharmacovigilance Analysis Using FAERS (2022 Q1-2025 Q1) with an Adapted Time-to-Onset Method.","authors":"Saisai Gu","doi":"10.2147/DHPS.S556918","DOIUrl":"10.2147/DHPS.S556918","url":null,"abstract":"<p><strong>Purpose: </strong>Tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist with rapidly expanding clinical use, requires detailed post-marketing pharmacovigilance to monitor emerging safety signals. This study aims to identify and characterize specific adverse events (AEs) associated with tirzepatide utilizing FDA Adverse Event Reporting System (FAERS).</p><p><strong>Patients and methods: </strong>The datasets were cleaned and standardized using Python, a programming language for data processing, and MySQL, a database management system, to ensure accuracy and consistency before analysis. Subsequently, AE signals were detected via four quantitative disproportionality algorithms, sorted and categorized by demographics, gender, and clinical prioritization, with a modified Weibull model developed to analyze AE onset timing.</p><p><strong>Results: </strong>A total of 67,305 cases (75.83% female) and 137,583 adverse events were identified related to tirzepatide. One hundred and forty-four AE signals showed statistically significant signals suggesting a potential association with tirzepatide, with several new including postmenopausal haemorrhage and menstrual disorder (implying regulatory interference on sex hormones), Wernicke's encephalopathy and sleep disorder (malnutrition caused by low intake). Pancreatitis, impaired gastric emptying, dehydration and cholelithiasis carried higher risks with serious clinical outcomes. Sleep disorder, delayed gastric emptying, and medullary thyroid cancer are more common in males; starvation ketoacidosis and incorrect injection site, in females. The median time-to-onset (TTO) was 6.36 days (Interquartile Range (IQR) 0.85-31.2) with the Weibull shape parameter (β) of 0.44, indicating an early failure profile.</p><p><strong>Conclusion: </strong>This study uncovered new risks of tirzepatide, including AEs associated with skin, menstruation, psychiatric and nervous system. Median TTO was corrected to within a week, highlighting the need for early monitoring before clinicians prescribe tirzepatide, and special attention should be given to patients who have pre-existing digestive dysfunction, malnutrition, or a family history of thyroid disease.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"18 ","pages":"556918"},"PeriodicalIF":3.4,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12794925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145965570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23eCollection Date: 2025-01-01DOI: 10.2147/DHPS.S553017
Mohammadrafie Khorgami, Mohammad Dalili, Bahareh Karimian
Digoxin toxicity poses a challenge for patients using the drug. Electrolyte disturbances, renal failure, and drug interactions are common predisposing factors. Hypothyroidism can increase the risk of digoxin toxicity primarily. This research reports a 7-year-old boy receiving digoxin 6 μg/kg/day presented with nausea and second-degree atrioventricular block secondary to ongoing digoxin toxicity. Initiation of levothyroxine for subclinical elevation of thyrotrophin resulted in rapid resolution of symptoms and normalization of digoxin levels.
{"title":"Digoxin Toxicity at Standard Doses in a Child with Subclinical Elevation of Thyrotrophin: A Case Report.","authors":"Mohammadrafie Khorgami, Mohammad Dalili, Bahareh Karimian","doi":"10.2147/DHPS.S553017","DOIUrl":"10.2147/DHPS.S553017","url":null,"abstract":"<p><p>Digoxin toxicity poses a challenge for patients using the drug. Electrolyte disturbances, renal failure, and drug interactions are common predisposing factors. Hypothyroidism can increase the risk of digoxin toxicity primarily. This research reports a 7-year-old boy receiving digoxin 6 μg/kg/day presented with nausea and second-degree atrioventricular block secondary to ongoing digoxin toxicity. Initiation of levothyroxine for subclinical elevation of thyrotrophin resulted in rapid resolution of symptoms and normalization of digoxin levels.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"265-267"},"PeriodicalIF":3.4,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12743475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145849069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-19eCollection Date: 2025-01-01DOI: 10.2147/DHPS.S564658
Bode Ireti Shobayo, Victor Saah Taylor, Bluefin Masell Freeman, James Saysay Kokro, Sampson K P Chea
Background: Globally, healthcare systems are currently facing a significant challenge in terms of antibiotic resistance. Healthcare professionals actively participate in the process of prescribing, dispensing and administering antibiotics.
Objective: We examined the knowledge, attitudes and practices regarding antibiotic use and antibiotic resistance among healthcare professionals working in a tertiary hospital located in Monrovia, Liberia.
Methods: A hospital-based cross-sectional survey was carried out from January to June, 2023 involving 61 healthcare workers at the ELWA Hospital, Liberia. A purposive sample of healthcare workers across diverse professional roles was surveyed using a structured questionnaire on antibiotic use and resistance. Data were analyzed in SPSS v25 using descriptive statistics to summarize participant characteristics and inferential tests to explore variable associations.
Results: Participants ages ranged from 20 to 60 years (mean = 40.7 ± 5) and nurses constituted the majority professional group (59%). Most respondents (68.9%) disagreed that antibiotics are effective against viral infections (OR = 0.45; p = 0.020). However, 36.1% believed antibiotics could be stopped when symptoms resolve and 24.6% believed leftover antibiotics could be reused (OR = 0.33; p = 0.002). Majority, 72.1% and 70.5%, reported never using antibiotics for body pain or headaches, respectively (OR = 3.67; p = 0.001 and OR = 4.78; p < 0.001). Despite this, 39.3% admitted to sometimes or always storing leftover antibiotics and 39.3% agreed or strongly agreed that stopping antibiotics early is safe (OR = 0.36; p = 0.016).
Conclusion: The study identified persistent gaps in healthcare workers' knowledge, attitudes, and practices regarding antibiotic use and resistance, despite encouraging awareness in some areas. Misconceptions such as premature discontinuation and reuse of leftover antibiotics were common. Findings underscore the need for targeted education and strengthened stewardship programs in Liberia's healthcare settings.
背景:在全球范围内,卫生保健系统目前正面临着抗生素耐药性方面的重大挑战。医护专业人员积极参与处方、配发和施用抗生素的过程。目的:我们调查了利比里亚蒙罗维亚一家三级医院医护人员关于抗生素使用和抗生素耐药性的知识、态度和做法。方法:于2023年1月至6月对利比里亚ELWA医院61名医护人员进行了以医院为基础的横断面调查。使用结构化的抗生素使用和耐药性问卷对不同专业角色的卫生保健工作者进行了有目的的抽样调查。在SPSS v25中对数据进行分析,采用描述性统计总结参与者特征,并采用推理检验探讨变量间的关联。结果:参与者年龄在20 ~ 60岁之间(平均= 40.7±5),以护士为主(59%)。大多数应答者(68.9%)不认为抗生素对病毒感染有效(OR = 0.45; p = 0.020)。然而,36.1%的人认为症状缓解后可以停用抗生素,24.6%的人认为剩余抗生素可以重复使用(OR = 0.33; p = 0.002)。大多数(72.1%和70.5%)报告从未因身体疼痛或头痛使用抗生素(or = 3.67; p = 0.001和or = 4.78; p < 0.001)。尽管如此,39.3%的人承认有时或总是储存剩余的抗生素,39.3%的人同意或强烈同意早期停用抗生素是安全的(or = 0.36; p = 0.016)。结论:该研究确定了卫生保健工作者关于抗生素使用和耐药性的知识、态度和实践方面的持续差距,尽管在某些领域鼓励了认识。过早停用和重复使用剩余抗生素等误解很常见。调查结果强调了在利比里亚的医疗环境中需要有针对性的教育和加强管理方案。
{"title":"Assessment of Knowledge, Attitudes, and Practices on Antibiotic Use and Resistance Among Healthcare Workers in Monrovia, Liberia: A Facility-Based Cross-Sectional Study.","authors":"Bode Ireti Shobayo, Victor Saah Taylor, Bluefin Masell Freeman, James Saysay Kokro, Sampson K P Chea","doi":"10.2147/DHPS.S564658","DOIUrl":"10.2147/DHPS.S564658","url":null,"abstract":"<p><strong>Background: </strong>Globally, healthcare systems are currently facing a significant challenge in terms of antibiotic resistance. Healthcare professionals actively participate in the process of prescribing, dispensing and administering antibiotics.</p><p><strong>Objective: </strong>We examined the knowledge, attitudes and practices regarding antibiotic use and antibiotic resistance among healthcare professionals working in a tertiary hospital located in Monrovia, Liberia.</p><p><strong>Methods: </strong>A hospital-based cross-sectional survey was carried out from January to June, 2023 involving 61 healthcare workers at the ELWA Hospital, Liberia. A purposive sample of healthcare workers across diverse professional roles was surveyed using a structured questionnaire on antibiotic use and resistance. Data were analyzed in SPSS v25 using descriptive statistics to summarize participant characteristics and inferential tests to explore variable associations.</p><p><strong>Results: </strong>Participants ages ranged from 20 to 60 years (mean = 40.7 ± 5) and nurses constituted the majority professional group (59%). Most respondents (68.9%) disagreed that antibiotics are effective against viral infections (OR = 0.45; p = 0.020). However, 36.1% believed antibiotics could be stopped when symptoms resolve and 24.6% believed leftover antibiotics could be reused (OR = 0.33; p = 0.002). Majority, 72.1% and 70.5%, reported never using antibiotics for body pain or headaches, respectively (OR = 3.67; p = 0.001 and OR = 4.78; p < 0.001). Despite this, 39.3% admitted to sometimes or always storing leftover antibiotics and 39.3% agreed or strongly agreed that stopping antibiotics early is safe (OR = 0.36; p = 0.016).</p><p><strong>Conclusion: </strong>The study identified persistent gaps in healthcare workers' knowledge, attitudes, and practices regarding antibiotic use and resistance, despite encouraging awareness in some areas. Misconceptions such as premature discontinuation and reuse of leftover antibiotics were common. Findings underscore the need for targeted education and strengthened stewardship programs in Liberia's healthcare settings.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"253-264"},"PeriodicalIF":3.4,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12640598/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-18eCollection Date: 2025-01-01DOI: 10.2147/DHPS.S557043
Changcheng Shi, Xinyi Li, Yan Wu, Wangjun Qin, Lihong Liu
Background: Polypharmacy has emerged as a major global public health concern. To mitigate its adverse effects, deprescribing has been introduced and integrated into clinical practice. This study aims to analyze the current research landscape and identify emerging trends in deprescribing from a bibliometric perspective.
Methods: Relevant studies on deprescribing published prior to December 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analysis and visualization of co-authorship, citation, co-citation, co-occurrence, and burst detection were performed using VOSviewer, CiteSpace, and Bibliometrix.
Results: A total of 1809 publications were identified, with a marked increase over the past decade. The field is dominated by contributions from developed countries, notably the United States, Australia, and Canada. Studies primarily focus on chronic conditions, such as psychiatric disorders, cardiometabolic diseases, and chronic pain, and the medications used to treat them. Influential publications highlighted barriers and facilitators of deprescribing, deprescribing tools, and deprescribing interventions and their associated outcomes. Burst detection analysis pointed to increasing attention on pharmaceutical care and implementation science.
Conclusion: This study presents the first comprehensive bibliometric overview of deprescribing. The findings demonstrate that the field has grown rapidly but remains dominated by developed countries and a limited set of chronic diseases. The integration of implementation science frameworks emerges as a promising approach to enhance the design and evaluation of deprescribing interventions. Future studies should broaden their scope to include a wider range of diseases and medications, and encourage greater participation from developing countries.
背景:综合用药已成为一个主要的全球公共卫生问题。为了减轻其不良影响,处方化已被引入并纳入临床实践。本研究旨在从文献计量学的角度分析当前的研究现状,并确定描述的新趋势。方法:检索Web of Science Core Collection数据库中2024年12月前发表的有关处方描述的相关研究。使用VOSviewer、CiteSpace和Bibliometrix对合著、被引、共被引、共现和突发检测进行文献计量学分析和可视化。结果:共确定了1809篇出版物,在过去十年中显著增加。该领域的贡献主要来自发达国家,特别是美国、澳大利亚和加拿大。研究主要集中于慢性疾病,如精神疾病、心脏代谢疾病和慢性疼痛,以及用于治疗这些疾病的药物。有影响力的出版物强调了开处方、开处方工具和开处方干预措施及其相关结果的障碍和促进因素。突发检测分析表明,越来越重视药学服务和实施科学。结论:本研究提出了第一个全面的文献计量学概述的处方。研究结果表明,该领域发展迅速,但仍由发达国家和有限的慢性疾病所主导。整合实施科学框架是加强处方性干预措施的设计和评估的一种有希望的方法。今后的研究应扩大其范围,包括更广泛的疾病和药物,并鼓励发展中国家更多地参与。
{"title":"Current Status and Research Trends in Deprescribing: A Bibliometric Review.","authors":"Changcheng Shi, Xinyi Li, Yan Wu, Wangjun Qin, Lihong Liu","doi":"10.2147/DHPS.S557043","DOIUrl":"10.2147/DHPS.S557043","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy has emerged as a major global public health concern. To mitigate its adverse effects, deprescribing has been introduced and integrated into clinical practice. This study aims to analyze the current research landscape and identify emerging trends in deprescribing from a bibliometric perspective.</p><p><strong>Methods: </strong>Relevant studies on deprescribing published prior to December 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analysis and visualization of co-authorship, citation, co-citation, co-occurrence, and burst detection were performed using VOSviewer, CiteSpace, and Bibliometrix.</p><p><strong>Results: </strong>A total of 1809 publications were identified, with a marked increase over the past decade. The field is dominated by contributions from developed countries, notably the United States, Australia, and Canada. Studies primarily focus on chronic conditions, such as psychiatric disorders, cardiometabolic diseases, and chronic pain, and the medications used to treat them. Influential publications highlighted barriers and facilitators of deprescribing, deprescribing tools, and deprescribing interventions and their associated outcomes. Burst detection analysis pointed to increasing attention on pharmaceutical care and implementation science.</p><p><strong>Conclusion: </strong>This study presents the first comprehensive bibliometric overview of deprescribing. The findings demonstrate that the field has grown rapidly but remains dominated by developed countries and a limited set of chronic diseases. The integration of implementation science frameworks emerges as a promising approach to enhance the design and evaluation of deprescribing interventions. Future studies should broaden their scope to include a wider range of diseases and medications, and encourage greater participation from developing countries.</p>","PeriodicalId":11377,"journal":{"name":"Drug, Healthcare and Patient Safety","volume":"17 ","pages":"239-252"},"PeriodicalIF":3.4,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12640142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145586325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}